Sopharma Group

After a successful privatization Sopharma becomes a private pharmaceutical company. The first years after privatization are a period of constant modernization and improvement. For the two years after the privatization period Sopharma unites six enterprises in a modern and dynamic corporate structure including: Sopharma AD, Unipharm ASD, Vramed AD, Pharmachim Holding AD, NIFHI AD and Rostbalkanpharm. Pharmaceutical plant “Sopharma – Vrabevo”, which is fully compliant with the European standards for Good Manufacturing Practices (GMP)

Sopharma fully licenses its production capacities according to the European standards for Good Manufacturing Practices. In 2004 Sopharma licensed its production facilities according to the European GMP which secured its strategic position after the EU accession in 2007. In the same year Sopharma increased its production capacity by adding another member to its group of companies – Bulgarian Rose – Sevtopolis AD. In 2005 Sopharma opened the most modern logistics center in Bulgaria (logistics terminal) for distribution of pharmaceutical products. The logistics center fully complies with the European Good Distribution Practice (GDP). Penetrating into distribution business by acquiring Sopharma Trading, acquiring its present form due to the merger of the five distributors – Sanita Trading, Caliman RTT JSC., Global Medical Ltd., Consumpharm and Elpharma.

Sopharma initiated the planning and construction process of a new highly technological tablet factory for the production of solid forms with doubled capacity and investment potential of over 40 million EUR. All activities related to planning, construction and validation fully comply with the European standards for pharmaceutical production and are approved by the Bulgarian Health Agency. For this project Sopharma received the First Class Investor Award.

In 2007 Sopharma made the next step in modernization and increased production capacity in the tablet production of Bulgarian Rose – Sevtopolis AD, Kazanlak. The official opening of the new plant for pharmaceutical substances took place in 2008. Being the only producer of ampoules in Bulgaria in 2007 Sopharma undertook a reconstruction of its ampoule facility in order to increase its production capacity.

Registration of the first original product of Sopharma in Western Europe.

Start of construction of two new production plants in Serbia and Bulgaria and establishing of a subsidiary in Poland. The next step in being an excellent public company. Listing on Warsaw Stock Exchange.

For the first time in the modern history of the company we open a new administrative office, more accessible to our guests and partners. For a third consecutive year Sopharma is given the “Best public company” award from the Capital Top 100 ranking. The new state-of-the-art solid-forms factory of Sopharma is operational and won three awards in the construction sector. The company takes several steps towards the consolidation of the Group.

Bulgarian Rose – Sevtopolis AD is finally merged into Sopharma. Sopharma Trading AD entered the Serbian Market. Sopharma AD acquires 68% of the capital of Veta Pharma AD. “Sopharma” AD acquires 51% of the capital of the Moldovan distributor of medicinal products RAP Pharma International. “Sopharma” AD acquires 75% of the successful start-up for the development and marketing of Aromania food supplements. “Medica” AD is merged into “Sopharma” AD. “Unipharm” AD is merged into “Sopharma” AD. The company celebrates its 85th anniversary.

“Sopharma Trading” AD acquires sole control over the companies “SCS Franchise” AD and “Sanita Franchising AD, which strengthens its position on the pharmacy market.” “Sopharma” AD sold the shares owned by it from the capital of “Aromania” AD, after having mastered all significant brands and activities. Аs a result of lengthy negotiations and an agreement reached with the other shareholders, a change in the shareholder structure of the subsidiary SIA “BRIZ” was entered in the Commercial Register of the Republic of Latvia as a result of which “Sopharma” AD remains the sole owner of the capital of the company.  “Sopharma” AD realized a successful issue of warrants amounting to over BGN 12 million.

https://www.sopharmagroup.com/en

Related posts

Leave a Comment